Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Theraclion has commercialized two CE-marked robotic HIFU platforms—SONOVEIN® for non-invasive treatment of varicose veins and ECHOPULSE® for benign thyroid nodules and breast fibroadenomas. Over 2,500 vein treatments have been performed with SONOVEIN®. The company continues to develop new generations of its devices and expand indications to include oncology applications such as breast cancer. Clinical data demonstrate safety and efficacy in approved indications with rapid patient recovery times due to the non-invasive nature of the technology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Theraclion.